Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 95
2006 80
2007 77
2008 82
2009 155
2010 178
2011 131
2012 156
2013 219
2014 294
2015 419
2016 376
2017 357
2018 379
2019 430
2020 405
2021 508
2022 408
2023 284
2024 121

Text availability

Article attribute

Article type

Publication date

Search Results

4,717 results

Results by year

Filters applied: . Clear all
Page 1
Corrigendum.
[No authors listed] [No authors listed] Future Oncol. 2023 Jul;19(21):1513. doi: 10.2217/fon-2020-1222c1. Epub 2023 Jul 4. Future Oncol. 2023. PMID: 37401438 Free article. No abstract available.
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, Hamilton E, Im SA, Nowecki Z, Sohn J, Laurentiis M, Jañez NM, Adamo B, Lee KS, Jung KH, Rubovszky G, Tseng LM, Lu YS, Yuan Y, Maxwell MJ, Haddad V, Khan SS, Rugo HS, Pistilli B. Bardia A, et al. Future Oncol. 2024 Mar;20(8):423-436. doi: 10.2217/fon-2023-0188. Epub 2023 Jun 30. Future Oncol. 2024. PMID: 37387213 Free article.
Corrigendum.
[No authors listed] [No authors listed] Future Oncol. 2022 Dec;18(38):4233. doi: 10.2217/fon-2022-0099e1. Epub 2022 Nov 28. Future Oncol. 2022. PMID: 36440800 Free article. No abstract available.
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Lee MA, Kitano M, Burris H, Bouattour M, Tanasanvimon S, McNamara MG, Zaucha R, Avallone A, Tan B, Cundom J, Lee CK, Takahashi H, Ikeda M, Chen JS, Wang J, Makowsky M, Rokutanda N, Żotkiewicz M, Kurland JF, Cohen G, Valle JW. Oh DY, et al. Future Oncol. 2023 Nov;19(34):2277-2289. doi: 10.2217/fon-2023-0468. Epub 2023 Sep 25. Future Oncol. 2023. PMID: 37746835 Free article. Review.
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Gupta C, Makowsky M, Kurland JF, Negro A, Sangro B. Abou-Alfa GK, et al. Future Oncol. 2023 Dec;19(38):2505-2516. doi: 10.2217/fon-2023-0486. Epub 2023 Sep 6. Future Oncol. 2023. PMID: 37671641 Free article. Review.
Corrigendum.
[No authors listed] [No authors listed] Future Oncol. 2023 Jan;19(3):271. doi: 10.2217/fon-2022-0456c1. Epub 2023 Jan 19. Future Oncol. 2023. PMID: 36655699 Free article. No abstract available.
Corrigendum.
[No authors listed] [No authors listed] Future Oncol. 2023 Jun;19(19):1379. doi: 10.2217/fon-2020-1213c1. Epub 2023 Jun 23. Future Oncol. 2023. PMID: 37350259 Free PMC article. No abstract available.
Corrigendum.
[No authors listed] [No authors listed] Future Oncol. 2023 Jun;19(17):1229. doi: 10.2217/fon-2021-0176c1. Epub 2023 Jun 9. Future Oncol. 2023. PMID: 37293712 Free PMC article. No abstract available.
Erratum.
[No authors listed] [No authors listed] Future Oncol. 2023 Nov;19(34):2333. doi: 10.2217/fon-2023-0088e1. Epub 2023 Oct 20. Future Oncol. 2023. PMID: 37860847 Free article. No abstract available.
Corrigendum.
[No authors listed] [No authors listed] Future Oncol. 2023 Jan;19(1):95. doi: 10.2217/fon-2021-1448c1. Epub 2023 Jan 25. Future Oncol. 2023. PMID: 36695657 Free article. No abstract available.
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Harrison CN, Gupta VK, Gerds AT, Rampal R, Verstovsek S, Talpaz M, Kiladjian JJ, Mesa R, Kuykendall AT, Vannucchi AM, Palandri F, Grosicki S, Devos T, Jourdan E, Wondergem MJ, Al-Ali HK, Buxhofer-Ausch V, Alvarez-Larrán A, Patriarca A, Kremyanskaya M, Mead AJ, Akhani S, Sheikine Y, Colak G, Mascarenhas J. Harrison CN, et al. Future Oncol. 2022 Sep;18(27):2987-2997. doi: 10.2217/fon-2022-0484. Epub 2022 Aug 11. Future Oncol. 2022. PMID: 35950489 Free article.
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T. Ohba A, et al. Future Oncol. 2022 Jun;18(19):2351-2360. doi: 10.2217/fon-2022-0214. Epub 2022 May 5. Future Oncol. 2022. PMID: 35510484 Free article.
Corrigendum.
[No authors listed] [No authors listed] Future Oncol. 2024 Feb;20(4):229. doi: 10.2217/fon-2022-0913c1. Epub 2024 Jan 12. Future Oncol. 2024. PMID: 38214122 Free article. No abstract available.
Corrigendum.
[No authors listed] [No authors listed] Future Oncol. 2024 Feb;20(6):349. doi: 10.2217/fon-2023-0468c1. Epub 2023 Dec 21. Future Oncol. 2024. PMID: 38126178 Free article. No abstract available.
Corrigendum.
[No authors listed] [No authors listed] Future Oncol. 2024 Jan;20(3):159-161. doi: 10.2217/fon-2022-1196c1. Epub 2024 Feb 7. Future Oncol. 2024. PMID: 38323464 Free article. No abstract available.
Margetuximab in HER2-positive metastatic breast cancer.
Gradishar WJ, O'Regan R, Rimawi MF, Nordstrom JL, Rosales MK, Rugo HS. Gradishar WJ, et al. Future Oncol. 2023 May;19(16):1099-1112. doi: 10.2217/fon-2022-1040. Epub 2023 May 12. Future Oncol. 2023. PMID: 37170847 Free article. Review.
KRASG12C mutation in metastatic colorectal cancer: a new target.
Ibrahim R, Saleh K, Chahine C, Khoury R, Khalife N, Lecesne A. Ibrahim R, et al. Future Oncol. 2023 Aug;19(24):1641-1643. doi: 10.2217/fon-2023-0223. Epub 2023 Aug 21. Future Oncol. 2023. PMID: 37602398 No abstract available.
2022 cancer statistics: Focus on lung cancer.
Jenkins R, Walker J, Roy UB. Jenkins R, et al. Future Oncol. 2023 Mar 20. doi: 10.2217/fon-2022-1214. Online ahead of print. Future Oncol. 2023. PMID: 36935641 Free article. Review.
Sex bias phenomenon in oral cancer: an insight.
Sengupta N, Sarode SC, Sarode GS, Anand R. Sengupta N, et al. Future Oncol. 2023 Jun;19(20):1381-1384. doi: 10.2217/fon-2023-0225. Epub 2023 Jul 5. Future Oncol. 2023. PMID: 37403625 No abstract available.
Advanced bladder cancer management: history in the making.
Zouein J, Boueri M, Kourie HR, Kattan J, Nemr E. Zouein J, et al. Future Oncol. 2023 Dec;19(39):2565-2567. doi: 10.2217/fon-2023-0908. Epub 2023 Dec 12. Future Oncol. 2023. PMID: 38084488 No abstract available.
Total neoadjuvant therapy for locally advanced rectal cancer: a narrative review.
Sellés EG, Pieretti DG, Higuero PP, Del Portillo EG, Macías VM, Domínguez MM, Mateos RF, Campos FL, Díaz-Gavela AA, Ferraris G, Couñago F. Sellés EG, et al. Future Oncol. 2023 Aug;19(25):1753-1768. doi: 10.2217/fon-2023-0481. Epub 2023 Aug 31. Future Oncol. 2023. PMID: 37650764 Review.
A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer.
Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, O'Malley DM, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath C 3rd, Dong Y, Veneris J, Pothuri B. Oaknin A, et al. Future Oncol. 2023 Aug;19(25):1709-1714. doi: 10.2217/fon-2022-1157. Epub 2023 Jun 29. Future Oncol. 2023. PMID: 37381977 Free article. Review.
Pathogenic role of 25-hydroxycholesterol in cancer development and progression.
Ejam SS, Saleh RO, Catalan Opulencia MJ, Najm MA, Makhmudova A, Jalil AT, Abdelbasset WK, Al-Gazally ME, Hammid AT, Mustafa YF, Sergeevna SE, Karampoor S, Mirzaei R. Ejam SS, et al. Future Oncol. 2022 Dec;18(39):4415-4442. doi: 10.2217/fon-2022-0819. Epub 2023 Jan 18. Future Oncol. 2022. PMID: 36651359 Review.
The roles of IDH1 in tumor metabolism and immunity.
Ni Y, Shen P, Wang X, Liu H, Luo H, Han X. Ni Y, et al. Future Oncol. 2022 Nov;18(35):3941-3953. doi: 10.2217/fon-2022-0583. Epub 2023 Jan 9. Future Oncol. 2022. PMID: 36621781 Free article. Review.
The 'hit-and-run' strategy and viral carcinogenesis.
Lasagna A, Cassaniti I, Sacchi P, Figini S, Baldanti F, Bruno R, Pedrazzoli P. Lasagna A, et al. Future Oncol. 2023 Feb;19(5):341-344. doi: 10.2217/fon-2022-1171. Epub 2023 Mar 15. Future Oncol. 2023. PMID: 36919920 No abstract available.
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.
Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel BC, Acar O, Aksoy S, Baytemur NK, Sahin E, Cabuk D, Basaran G, Paydas S, Yaren A, Guven DC, Erdogan AP, Demirci U, Yasar A, Bayoglu İV, Hizal M, Gulbagci B, Paksoy N, Davarci SE, Yilmaz F, Dogan O, Orhan SO, Kayikcioglu E, Aytac A, Keskinkilic M, Mocan EE, Unal OU, Aydin E, Yucel H, Isik D, Eren O, Uluc BO, Ozcelik M, Hacibekiroglu I, Aydiner A, Demir H, Oksuzoglu B, Cilbir E, Cubukcu E, Cetin B, Oktay E, Erol C, Okutur SK, Yildirim N, Alkan A, Selcukbiricik F, Aksoy A, Karakas Y, Ozkanli G, Duman BB, Aydin D, Dulgar O, Er MM, Teker F, Yavuzsen T, Aykan MB, Inal A, Iriagac Y, Kalkan NO, Keser M, Sakalar T, Menekse S, Kut E, Bilgin B, Karaoglanoglu M, Sunar V, Ozdemir O, Turhal NS, Karadurmus N, Yalcin B, Nahit Sendur MA. Kahraman S, et al. Future Oncol. 2023 Mar;19(10):727-736. doi: 10.2217/fon-2022-1287. Epub 2023 May 3. Future Oncol. 2023. PMID: 37133230
Application of Cherenkov radiation in tumor imaging and treatment.
Bianfei S, Fang L, Zhongzheng X, Yuanyuan Z, Tian Y, Tao H, Jiachun M, Xiran W, Siting Y, Lei L. Bianfei S, et al. Future Oncol. 2022 Sep;18(27):3101-3118. doi: 10.2217/fon-2022-0022. Epub 2022 Sep 6. Future Oncol. 2022. PMID: 36065976 Review.
Cetuximab every 2 weeks versus standard weekly dosing administration schedule.
Bokemeyer C, Ciardiello F, Dubreuil O, Guigay J, Kasper S, Pfeiffer P, Pinto C, Yamaguchi K, Yoshino T, Zielinski C, Esser R, Tabernero J. Bokemeyer C, et al. Future Oncol. 2024 Mar;20(7):393-407. doi: 10.2217/fon-2023-0282. Epub 2023 Oct 18. Future Oncol. 2024. PMID: 37850363 Free article. Review.
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
Solomon BJ, Bauer TM, K Mok TS, Liu G, Mazieres J, Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Solomon BJ, et al. Future Oncol. 2023 May;19(14):961-973. doi: 10.2217/fon-2022-1289. Epub 2023 Jun 12. Future Oncol. 2023. PMID: 37306090 Free article. Review.
The beginning: diagnosis and selecting your doctor.
Clements J, Fleischman A, Lerner V, Ruiz C. Clements J, et al. Future Oncol. 2023 Jun;19(17):1209. doi: 10.2217/fon-2023-0402. Epub 2023 Jun 2. Future Oncol. 2023. PMID: 37265433 Free article.
4,717 results